EQNX::TICKER_START (NASDAQINBS),NASDAQ:CDIONASDAQCDIO)(NASDAQ:BIAFNASDAQBIAF,(NASDAQ:TRIBNASDAQ),(NASDAQ:SOBRSOBR) EQNX::TICKER_END

PALM BEACH, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Due to the expanding consumption of illicit drugs & alcohol across the globe the Drug Screening market is poised to grow substantially in the coming years. Drug abuse and alcohol consumption are growing worldwide. According to the World Drug Report 2023, in 2021, 1 in every 17 people aged 15–64 in the world had used a drug in the past 12 months. The number of users grew from 240 million in 2011 to 296 million in 2021 or 5.8% of the global population aged 15-64. This is a 23% increase, partly due to population growth. Other drugs like Cannabis the second most used drug, with an estimated 219 million users i.e. 4.3% of the global adult population in 2021. In 2021, according to the US Department of Transportation, National Highway Traffic Safety Administration (NHTSA), 13,384 people died in alcohol-impaired driving crashes, i.e. a 14% rise from last year. A report from MarketsAndMarkets projected that: “The global drug screening market, valued at US$7.7 billion in 2023, is forecasted to grow at a robust CAGR of 16.6%, reaching US$9.1 billion in 2024 and an impressive US$19.5 billion by 2029.North America dominates the drug screening market. This market is projected to reach USD 9.3 billion by 2029, at a CAGR of 16.4% during the forecast period. The expanding consumption of illicit drugs & alcohol will advance raise the development of drug screening products & services on the road, thereby driving the overall market growth.”   Active companies in news today include:   Intelligent Bio Solutions Inc. (NASDAQINBS), Cardio Diagnostics Holdings, Inc. NASDAQ: CDIONASDAQCDIO)(NASDAQ: BIAFNASDAQBIAF, Trinity Biotech plc (NASDAQ: TRIBNASDAQ), SOBR Safe, Inc. (NASDAQ: SOBRSOBR).

SOBR Safe (NASDAQSOBR) (“SOBRsafe”), a provider of next-generation transdermal alcohol detection technology, recently announced the launch of its fully integrated enterprise software solution that is expected to transform how health providers monitor and manage alcohol compliance. “To complement its software solution for point-of-care screening SOBRcheck(TM) and continuous monitoring SOBRsure(TM), this enterprise software is designed to enhance responsiveness to treatment, reduce recidivism and drive positive patient outcomes,” reads an article discussing the launch.

SOBR Safe (NASDAQSOBR) (“SOBRsafe”) is a provider of next-generation transdermal alcohol screening and monitoring solutions. The company recently launched a national campaign that seeks to introduce its technology offerings – the SOBRcheck(TM) stationary alcohol screening device, the SOBRsure(TM) discreet alcohol monitoring wristband, and the SOBRsafe(TM) software platform powering reporting – to behavioral health providers and, as a result, drive sales growth into 2025. “The company aims to present its technology to over 45,000 decision-makers in the behavioral health space, having partnered with recognized leaders in public relations and digital and social media marketing,” reads an article discussing the campaign.

SOBR Safe (NASDAQSOBR) (“SOBRsafe”), a provider of next-generation transdermal alcohol detection solutions, earlier this year began the sale of its SOBRsure(TM) wearable continuous alcohol monitoring device in Australia and New Zealand following a 90-day proof-of-concept. “This overseas milestone was made possible through an international channel partnership with Drug Testing Business Success, the leading drug and alcohol testing service provider in the region,” reads a recent article.

SOBRsafe (NASDAQSOBR), a Colorado-based provider of next-generation transdermal alcohol detection technology, has just announced the launch of its fully integrated enterprise software solution that is expected to transform how health providers monitor and manage alcohol compliance. Designed to complement its software solution for point-of-care screening (SOBRcheck(TM)) and continuous monitoring (SOBRsure(TM)), this enterprise software is designed to enhance responsiveness to treatment, reduce recidivism and drive positive patient outcomes ( https://ibn.fm/GGnkx ).

SOBRsafe (NASDAQSOBR) has released SOBRsure, a new wristband device that uses transdermal technology to detect alcohol levels through the skin, providing real-time monitoring to support sobriety and recovery. With a sleek, user-friendly design and GPS tracking, the device offers continuous alcohol detection, instant alerts, and the option to access historical reports through a premium subscription. CEO David Gandini emphasizes SOBRsure as both a technological breakthrough and a support system for individuals with alcohol use disorder, aiming to promote accountability and peace of mind for families, employers, and users. Available now, the wristband retails for $249, with subscriptions starting at $39.99 per month.

SOBRsafe (NASDAQSOBR), a provider of next-generation transdermal alcohol screening and monitoring solutions, recently raised $8.2 million in gross proceeds from a private placement with certain institutional investors. The company expects to use the net proceeds from the offering for working capital and general corporate purposes ( https://ibn.fm/xM074 ).

SOBR Safe (NASDAQSOBR) (“SOBRsafe”) develops and sells a passive, preventative alcohol screening device called the SOBRcheck(TM) and a continuous alcohol monitoring wristband called SOBRsure(TM). “SOBRcheck is fitted with two sensors, one of which scans biometrics data from a user’s fingerprint, with the other detecting any alcohol excreted from the pores in the tip of the finger. The device is powered by the SOBRsafe software platform, which relays results in real time, improving employee throughput at point-of-care facilities. The SOBRsure(TM) device is equally configured to provide app-based reporting via the SOBRsafe platform, support GPS tracking and send removal alerts,” a recent article reads.

SOBRsafe (NASDAQSOBR) announced its compliance with Nasdaq’s listing standards, meeting minimum bid price, public float, and stockholders’ equity requirements per the August 2024 Nasdaq Hearings Panel decision. As a result, SOBRsafe’s common stock will remain listed on the Nasdaq Capital Market. The company will undergo a one-year monitoring period starting Oct. 30, 2024, during which any recurrence of non-compliance with the stockholders’ equity rule will result in an immediate Delist Determination Letter, requiring a new hearing request without a compliance grace period.

DENVER, CO / ACCESSWIRE / October 31, 2024 / SOBR Safe, Inc. (NASDAQSOBR) ("SOBRsafe"), provider of next-generation transdermal alcohol detection solutions, today announced that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), the public float requirement under Nasdaq Listing Rule 5550(a)(4) and the stockholders' equity requirement (the "Equity Rule") under Nasdaq Listing Rule 5550(b)(1), as required by the Nasdaq Hearings Panel decision dated August 2024. Accordingly, the Company's common stock will continue to be listed and trade on The Nasdaq Capital Market under the symbol "SOBR".